Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NBTX | US
-0.13
-0.39%
Healthcare
Biotechnology
30/06/2024
24/04/2026
33.58
33.62
34.27
33.34
Nanobiotix S.A. a clinical-stage biotechnology focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3 a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma head and neck cancers liver cancers prostate cancer pancreatic cancer esophageal cancer rectal cancer and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China South Korea Singapore and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris France.
View LessLow Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
61.0%1 month
76.1%3 months
96.6%6 months
94.4%-
48.31
65.02
-2.04
0.51
-2.45
5.22
-
-22.30M
1.60B
1.60B
-
-253.32
-
182.10
-198.69
2.52
0.08
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.83
Range1M
5.66
Range3M
21.34
Rel. volume
0.83
Price X volume
1.96M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings Inc. | HRMY | Biotechnology | 30.8 | 1.75B | -3.99% | 18.16 | 40.71% |
| Vericel Corporation | VCEL | Biotechnology | 35.64 | 1.75B | 3.60% | 4.17K | 39.42% |
| ANI Pharmaceuticals Inc | ANIP | Biotechnology | 78.64 | 1.65B | 0.74% | 50.68 | 68.04% |
| Nuvation Bio Inc | NUVB | Biotechnology | 4.89 | 1.64B | -2.98% | n/a | 112.61% |
| Avidity Biosciences Inc. | RNA | Biotechnology | 13.49 | 1.59B | -2.60% | n/a | 0.69% |
| Pharvaris B.V | PHVS | Biotechnology | 28.63 | 1.55B | 4.91% | n/a | 0.04% |
| Ocular Therapeutix Inc | OCUL | Biotechnology | 9.49 | 1.48B | -1.04% | n/a | 19.83% |
| Innoviva Inc | INVA | Biotechnology | 23.57 | 1.47B | 0.38% | 11.32 | 67.72% |
| Immunocore Holdings plc | IMCR | Biotechnology | 29.3 | 1.47B | 0.24% | n/a | 131.69% |
| Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 13.2823 | 1.46B | 0.32% | n/a | 21.43% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.6 | 1.46B | 3.03% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 39.11 | 1.23B | -1.21% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 32.87 | 951.75M | 0.70% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.44 | 790.55M | 1.30% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.7 | 737.79M | 2.31% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.01 | 694.62M | -0.17% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.33 | 528.66M | -1.26% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -0.91% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.53 | 390.77M | -0.88% | 34.27 | 26.82% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.48 | 337.57M | 8.41% | n/a | 3644.76% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.45 | 0.53 | Cheaper |
| Ent. to Revenue | 5.22 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 65.02 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 96.59 | 72.80 | Riskier |
| Debt to Equity | -2.04 | -1.23 | Cheaper |
| Debt to Assets | 0.51 | 0.25 | Expensive |
| Market Cap | 1.60B | 3.66B | Emerging |